Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, announces it has completed a majority growth investment in Concord Biomedical Sciences and Emerging Technologies, Inc. (“CBSET” or the “Company”), a leading Boston-area provider of translational research and product development services for the medical device, pharmaceutical, diagnostic, and biomedical research industries. CBSET offers a broad range of preclinical research and testing services as well as expert regulatory support for both FDA and global submissions.
Read the full article: Arlington Capital Partners Announces Majority Growth Investment in CBSET //
Source: https://www.businesswire.com/news/home/20251001678891/en/Arlington-Capital-Partners-Announces-Majority-Growth-Investment-in-CBSET